First-in-Class Therapeutics,
Born from First-Principles Models
With GALILEO™, we've discovered 192 compounds and advanced 67 assets in cellular models of disease across 12 therapeutic targets for multiple areas of biology. Our data was validated by preeminent researchers and scientists at premier academic and corporate laboratories
Drug Pipeline
Virology
Our virology program is developing the next generation of antivirals that have broader activity and demonstrate best-in-class antiviral characteristics.
Lead Asset
1
MDL-001 a direct acting pan antiviral
Targets
10
Assets Validated
56
via In-Vitro Cell Model of Disease
Drug Pipeline
Oncology
Our Oncology program has discovered potential therapeutics for two broad spectrum oncology targets, AXL and BRD4.
Lead Asset
1
MDL-4102 a potent and selective BRD4 inhibitor
Targets
2
Assets Validated
11
via In-Vitro Cell Model of Disease
Emerging Therapeutic Areas
With GALILEO™ we're unlocking new therapies
Emerging Area
Inflammation
We recently launched a program and completed in-silico discovery work for compounds against multiple targets related to ANCA-Associated Vasculitis (AAV)
ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is a group of rare, life-threatening, immune disorders, which are characterized by a “necrotizing inflammatory process that predominantly affects small and medium-sized blood vessels” such as arterioles, capillaries, and venules.
There are three subtypes of AAV that include Granulomatosis with polyangiitis (GPA, previously Wegener’s disease), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, previously Churg-Strauss syndrome)
TargetS
4
Undisclosed
Compounds
50+
via In Silico Discovery
Emerging Area
Longevity
Our longevity program is focused on the growing evidence linking gastrointestinal dysmotility to numerous indications, including mental health, metabolism, and neurological disorders.
Target
1
Undisclosed
Compound
1
via In Silico Discovery